RAPID DEVELOPMENT OF RESISTANCE TO ANTIFOLATES INVITRO - POSSIBLE CLINICAL IMPLICATION

被引:17
作者
SOBRERO, A
ASCHELE, C
ROSSO, R
NICOLIN, A
BERTINO, JR
机构
[1] IST NAZL RIC CANC,DEPT PHARMACOL,I-16132 GENOA,ITALY
[2] MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021
关键词
D O I
10.1093/jnci/83.1.24
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Within three repeated 7-day incubation periods with either methotrexate (MTX) or trimetrexate (TMTX), human colon adenocarcinoma cells (HCT-8) developed high levels of resistance to these drugs, as evidenced by approximately 20- and 50-fold increases, respectively, in the median effective doses. Similarly, within six short-term exposures (4 hours) to the same drugs, a high degree of resistance developed in the cells. Alternating 4-hour treatment cycles with MTX and TMTX did not delay the onset of resistance to these antimetabolites in the HCT-8 cells. The same strategy produced no better results than giving either MTX or TMTX alone to (C57BL/6 X DBA/2)F1 mice bearing murine leukemia P388 cells. Furthermore, HCT-8 cells resistant to short-term (4-hour) exposure to MTX were cross-resistant to the same drug given for 7 days continuously, and cells resistant to MTX given continuously for 7 days were cross-resistant to the same drug given for 4 hours. Analogous results were obtained with TMTX, indicating that, under these circumstances, changing the schedule of administration of the same agent does not overcome resistance to it. The clinical relevance of these data to prolonged adjuvant chemotherapy, as well as loco-regional and continuous-infusion chemotherapy, is discussed.
引用
收藏
页码:24 / 28
页数:5
相关论文
共 18 条
[1]   2,4-DIAMINO-5-METHYL-6-[(3,4,5-TRIMETHOXYANILINO)METHYL]QUINAZOLINE (TMQ), A POTENT NON-CLASSICAL FOLATE ANTAGONIST INHIBITOR .1. EFFECT ON DIHYDROFOLATE-REDUCTASE AND GROWTH OF RODENT TUMORS INVITRO AND INVIVO [J].
BERTINO, JR ;
SAWICKI, WL ;
MOROSON, BA ;
CASHMORE, AR ;
ELSLAGER, EF .
BIOCHEMICAL PHARMACOLOGY, 1979, 28 (12) :1983-1987
[2]  
BERTINO JR, 1987, NATL CANCER I MONOGR, V5, P87
[3]  
COWAN KH, 1984, J BIOL CHEM, V259, P793
[4]  
DEVITA VT, 1989, CANCER PRINCIPLES PR, P276
[5]   EVALUATION OF OPTIMAL DURATION OF CHEMOTHERAPY IN FAVORABLE-PROGNOSIS DISSEMINATED GERM-CELL TUMORS - A SOUTHEASTERN-CANCER-STUDY-GROUP PROTOCOL [J].
EINHORN, LH ;
WILLIAMS, SD ;
LOEHRER, PJ ;
BIRCH, R ;
DRASGA, R ;
OMURA, G ;
GRECO, FA .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (03) :387-391
[6]   A MATHEMATICAL-MODEL OF DRUG-RESISTANCE APPLIED TO TREATMENT FOR SMALL-CELL LUNG-CANCER [J].
GREGORY, WM ;
BIRKHEAD, BG ;
SOUHAMI, RL .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (03) :457-461
[7]   LONG-TERM SURVIVAL OF ADVANCED REFRACTORY OVARIAN-CARCINOMA PATIENTS WITH SMALL-VOLUME DISEASE TREATED WITH INTRAPERITONEAL CHEMOTHERAPY [J].
HOWELL, SB ;
ZIMM, S ;
MARKMAN, M ;
ABRAMSON, IS ;
CLEARY, S ;
LUCAS, WE ;
WEISS, RJ .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (10) :1607-1612
[8]  
HOWELL SB, 1985, HARRISONS PRINCIPLES, V7, P93
[9]  
JACKSON RC, 1988, SEMIN ONCOL, V15, P1
[10]   TRIMETREXATE - A 2ND GENERATION FOLATE ANTAGONIST IN CLINICAL-TRIAL [J].
LIN, JT ;
BERTINO, JR .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (12) :2032-2040